QuanterixQTRX
QTRX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
204% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $436K
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
22% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 45
3.46% more ownership
Funds ownership: 87.37% [Q3] → 90.84% (+3.46%) [Q4]
2% more funds holding
Funds holding: 149 [Q3] → 152 (+3) [Q4]
14% less capital invested
Capital invested by funds: $435M [Q3] → $372M (-$62.6M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
126%
upside
Avg. target
$16.50
148%
upside
High target
$18
171%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Sung Nam 0% 1-year accuracy 0 / 2 met price target | 171%upside $18 | Sector Outperform Maintained | 25 Mar 2025 |
Canaccord Genuity Kyle Mikson 33% 1-year accuracy 9 / 27 met price target | 126%upside $15 | Buy Maintained | 18 Mar 2025 |
Financial journalist opinion
Based on 10 articles about QTRX published over the past 30 days
Neutral
Business Wire
14 hours ago
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria. This new extraction kit enables researchers to measure low-concentration biomar.
Neutral
Business Wire
1 week ago
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTRX) (“Quanterix” or the “Company”), today announced that it intends to vote AGAINST the Company's proposed merger with Akoya Biosciences, Inc. (“Akoya”) (Nasdaq: AKYA) at the upcoming Quanterix Special Meeting of shareholders. As a significant investor in the Company since 2018, Tikvah believes the.
Neutral
Seeking Alpha
2 weeks ago
Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Joshua Young - Head of IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Sung Ji Nam - Scotiabank Operator Thank you for standing by. My name is Kathleen and I will be your conference operator today.
Neutral
Business Wire
2 weeks ago
Quanterix Releases Financial Results for the Fourth Quarter of 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment,” said Masoud Toloue, Chief Executive Officer of Quanterix. “Our ability to grow in a difficult environm.
Neutral
Business Wire
2 weeks ago
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA), and has also nominated three highly qualified, independent candidates for election to the Company's Board of Directors.
Neutral
Business Wire
2 weeks ago
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, March 17, 2025, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2024 financial results. Quanterix will issue a press release regarding fourth quarter and full year 2024 financial results prior to the conference call on Monday, March 17, 2025, after the market close.
Neutral
Business Wire
3 weeks ago
Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued a presentation to Quanterix shareholders in connection to Kent Lake's opposition to the Company's proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake's full presentation is available at https://kentlake.s3.us-west-1.amazonaws.com/QTRX-AKYA_KLPRVot.
Neutral
Business Wire
4 weeks ago
Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 6.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), announced today it has nominated three highly qualified, independent candidates for election to the Company's Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders (the “Annual Meeting”). Kent Lake issued the following statement: “We have never before taken a public activist stance at.
Neutral
Business Wire
4 weeks ago
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed acquisition of Akoya Biosciences, which will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. Quanterix issued the following statement: Quanterix's proposed acquisition of Akoy.
Neutral
Accesswire
4 weeks ago
The Schall Law Firm Invites Shareholders With Losses In Quanterix Corporation To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™